Drug intelligence / Profile preview

galotam

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Galotam is a **phosphodiesterase 5 (PDE5) inhibitor** indicated for the treatment of **erectile dysfunction (ED) in men** and **pulmonary arterial hypertension in both men and women**. It acts by inhibiting the PDE5 enzyme, preventing it from breaking down cyclic GMP, which leads to relaxation of smooth muscle and increased blood flow in the penis (for ED) and relaxation of pulmonary vasculature (for pulmonary hypertension). Physical sexual stimulation is required for Galotam to be effective in ED. This medication is available by prescription only[1].

Brand names: galotam

Targets

PDE5 (Phosphodiesterase 5A)PDE6 (Phosphodiesterase 6)

Beyond the preview

Go deeper on galotam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on galotam.

Explore the full profile